NCT05045443View on ClinicalTrials.gov

Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 22, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

January 4, 2024

Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
DRUG

Curcumin

Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement

DIETARY_SUPPLEMENT

Standard of Care

As per institution protocol for Standard of nutritional Care

Trial Locations (1)

11566

Pediatric Hematology Oncology and BMT Unit, Faculty of Medicine Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05045443 - Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter